Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 15INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Nasopharyngeal Carcinoma 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Sarcoma 2Respiratory Tract Diseases 2Lung Diseases 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Recurrence 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non Squamous Non Small Cell Lung Cancer 1Neoplasms by Site 1Neoplasm Metastasis 1Lymphoma, Extranodal NK-T-Cell 1Hodgkin Disease 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × camrelizumab × Clear all
NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
80 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
99 enrolled
BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡